The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Since cutting the ribbon on its inaugural commercial-scale Smart Factory in Bridgewater earlier this year, the San ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...